Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of the following treatments for COVID-19:
- Sotrovimab (GlaxoSmithKline and Vir Biotechnology)
- Molnupiravir (Merck)
- PF-07321332/ritonavir (Paxlovid, Pfizer)
- Fluvoxamine (investigator initiated)
